Clinical Trial Update: Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488 [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating a booster dose of GlaxoSmithKline's 10-valent pneumococcal conjugate vaccine and a single dose of the 23-valent plain p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Haemophilus Influenzae Type Disease
• Hepatitis B
• Pertussis
• Pneumococcal Disease
• Poliomyelitis
• Tetanus

Drugs mentioned

• Pneumococcal conjugate vaccine, 10-valent (PCV10) (Pneumococcal conjugate vaccine, 10-valent)
• Pneumococcal polysaccharide vaccine, 23-valent (PPV23) (Pneumococcal polysaccharide vaccine, 23-valent)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Acellular Pertussis, Tetanus | Phase 2 | Status: COMPLETED